|
Liver carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the CASP3 rs12108497 polymorphism may play a role in the development of HCC among smoking individuals in the Chinese population.
|
26758428 |
2016 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that restoration of DLC1 tumor suppressor gene expression in the DLC1-negative Focus and 7703K human hepatocellular carcinoma (HCC) cell lines induced caspase-3 mediated apoptosis, reduced cell growth in vitro and tumorigenicity in vivo and diminished the ability to migrate through Matrigel, a property suggestive of metastatic potential in vivo.
|
18497990 |
2008 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although we recently demonstrated that cytoplasmic AFP might interact with caspase-3 and inhibit the signal transduction of apoptosis in human hepatocellular carcinoma (HCC) cells, the details of this interaction are not clear.
|
28653316 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
Parvovirus B19-induced apoptosis of hepatocytes.
|
15220451 |
2004 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The variation of circulating miR-221 levels in relation to Sorafenib treatment were assayed in the animal models and in two independent cohorts of patients with advanced HCC.<b>Results:</b> MiR-221 over-expression was associated with Sorafenib resistance in two HCC animal models and caspase-3 was identified as its target gene, driving miR-221 anti-apoptotic activity following Sorafenib administration.
|
28096271 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
An elevation in serum level of the inflammatory (TNF-ά, CRP, and Argenase), hepatic apoptotic markers (P53, Bax, and Caspase 3) and a reduction of Blc2% were recorded in HCC rats.
|
28821164 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
TUNEL assay revealed that resveratrol induced cell apoptosis by increasing HCC apoptosis rate from 3±0.78% to 16±1.12% with upregulation of B‑cell lymphoma (Bcl)‑2 associated X, apoptosis regulator and cleaved‑poly (ADP‑Ribose) polymerase 1 (PARP), and downregulation of Bcl‑2, caspase‑3, caspase‑7 and PARP.
|
28983625 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, we found that inhibition of p38 by SB202190 abrogated enhanced hepatocyte death, compensatory proliferation and HCC induced by DEN in Caspase-3-deficient mice.
|
29752472 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Interestingly, MK-AS also clearly downregulated the protein level of Bcl-2, and upregulated p53, Bax, and caspase-3 in the hepatocellular carcinoma tissue.
|
17303011 |
2007 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast, here we demonstrated apoptosis induction in human lung epithelial carcinoma (A549), human hepatocarcinoma and Vero cells upon infection with the attenuated Candid#1 strain of, JUNV as determined by phosphatidylserine (PS) translocation, Caspase 3 (CASP3) activation, Poly (ADP-ribose) polymerase (PARP) cleavage and/or chromosomal DNA fragmentation.
|
24918927 |
2014 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.
|
17983802 |
2007 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Plumbagin promotes human hepatoma SMMC-7721 cell apoptosis via caspase-3/vimentin signal-mediated EMT.
|
31409969 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggested that PPW-induced apoptosis involved a caspase-3-mediated mitochondrial pathway and may have potential as a cancer chemopreventive and therapeutic agent for the prevention and treatment of HCC.
|
26555544 |
2016 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, downregulation of PHLDA gene, upregulation of ACIN1 protein and caspase-3 activation in exposed cells indicated that endosulfan can trigger apoptotic cascade in hepatocellular carcinoma cells.
|
26615145 |
2015 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway.
|
31368655 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Lenalidomide induces apoptosis and inhibits angiogenesis via caspase‑3 and VEGF in hepatocellular carcinoma cells.
|
27748917 |
2016 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Caspase-3 gene transfected with LIGHT gene: can it be used for therapy of human hepatocellular carcinoma?
|
18298346 |
2008 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
BER significantly reduced doxorubicin (DOX)-triggered HCC repopulation in vitro and in vivo through inhibiting Caspase-3-iPLA2-COX-2 pathway.
|
31563690 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Sinoporphyrin sodium based sonodynamic therapy induces anti-tumor effects in hepatocellular carcinoma and activates p53/caspase 3 axis.
|
30660690 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Huh-7 human hepatoma tumor growth in nude mice with a defect of T cell function was significantly inhibited by Ad.PPThIL-18CPP32- compared with Ad.hProIL-18 encoding immature IL-18.
|
15044962 |
2004 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results reveal that both methods are suitable and sensitive techniques for the in situ detection of apoptosis, however, they also demonstrate that immunohistochemistry for active caspase 3 and single-stranded DNA have differential sensitivities in HCC and CRC.
|
18027258 |
2007 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Apoptosis was selectively induced following infection of HuH7 cells with RevCasp3, demonstrating that retroviruses expressing RevCasp3 are of potential interest for the treatment of hepatocellular carcinomas and other tumour types.
|
15521050 |
2005 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The present study shows that lupeol can inhibit cell proliferation of hepatocellular carcinoma (HCC) HCCLM3 cells in a time- and dose-dependent manner, through caspase-3 dependent activation and Poly ADP-Ribose Polymerase (PARP) cleavage.
|
26004524 |
2015 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
ZnONPs significantly reduced the elevated serum levels of HCC-related tumor markers alphafetoprotein and alpha-l-fucosidase and the apoptotic marker caspase-3 compared with the untreated HCC rats.
|
27718258 |
2017 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Activated caspase-3 increases 8-fold in Jurkat E6-1 cells and 40% in rat hepatocellular carcinoma and mouse fibrosarcoma cells by 3 h post treatment.
|
28428881 |
2017 |